Inflammatix, a Sunnyvale, CA-based molecular diagnostics company, closed a $57m Series E financing.
The round was led by Khosla Ventures and Think.Health, with participation from Northpond Ventures, D1 Capital Partners, Iberis Capital, Vesalius BioCapital, OSF Healthcare, RAW Ventures, and others.
The company intends to use the funds for support regulatory filing and early commercialization its lead product, the TriVerity™ Acute Infection and Sepsis Test (TriVerity).
Led by Dr. Timothy Sweeney, CEO, Inflammatix is a molecular diagnostics company developing novel diagnostics that rapidly read a patient’s immune system to improve patient care and reduce major public health burdens. The Inflammatix tests will be developed to run on the company’s sample-to-answer isothermal instrument platform, enabling the power of precision medicine at the point of care.
TriVerity, a blood test performed on Inflammatix’s novel Myrna™ Instrument, is designed to simultaneously determine whether an infection is present, and how likely a patient will need ICU-level interventions.
After receiving Breakthrough Device Designation from the U.S. Food and Drug Administration (FDA) in November 2023 and completing the SEPSIS-SHIELD study [NCT04094818], Inflammatix recently submitted a regulatory packet to the FDA for the TriVerity Test. The company hopes to receive FDA clearance later this year.
FinSMEs
12/09/2024